A Thai team isolated lytic phage Eco-MTCMU-01 from wastewater and assigned it to Vectrevirus. Its genome contained no identifiable lysogeny, resistance, virulence or anti-CRISPR genes. Phage alone did not eradicate bacteria by 24 hours, but with cefepime it produced FICI 0.25 and reduced MIC/MBC from 32-64 to below 8 micrograms/mL in a representative ESBL E. coli isolate. This is in-vitro synergy, not a ready therapy.
Key findings
- Eco-MTCMU-01 is a lytic Autographiviridae/Vectrevirus with no detected screened risk genes and a narrow host range covering selected E. coli isolates. Phage alone did not eradicate bacteria at 24 hours; phage plus cefepime yielded FICI 0.25 and reduced MIC/MBC from 32-64 to
Why this matters globally
Phage-antibiotic combinations may restore antibiotic activity, lower dosing or slow resistance, but narrow host range and phage resistance require cocktails and surveillance.
Thai researcher contribution
Mahidol University's AMRIC and Faculty of Pharmacy collaborated with KMUTNB biotechnology researchers from Thai wastewater isolation through genomics and functional synergy testing.
Limitations to consider
Key synergy evidence comes from a representative isolate in vitro. Animal infection, pharmacokinetics, immune neutralisation, endotoxin control and resistance evolution are untested. Absence of known genomic risk genes is not a complete safety guarantee, and host range is limited.